Companies › Alethia Biotherapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sotevtamab Anti-tumor-associated secreted clusterin (TA-sCLU) monoclonal antibody | CLU | Phase 2 | Metastatic Colorectal Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06225843 | Sotevtamab | Phase 2 | Metastatic Colorectal Cancer | Oncology | Mar 2026 |
–
CatalYm Solstice Oncology CrystalGenomics Partner Therapeutics STCube
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.